We are live on ! Find out more

ARK Genomic Revolution ETF

ARKG

Market cap $2.05B

51.40 USD

-3.71

6.73%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

51.40

0.00

0%

1 day

-6.73%

5 days

6.53%

1 month

-5.2%

3 months

30.92%

6 months

72.08%

Year to date

76.15%

1 year

72.54%

5 years

-33.66%

10 years

207.42%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 50%

Negative 0%

ARKG: Revolutionary Science, Unremarkable Returns

I rate ARK Genomic Revolution ETF a HOLD with MODERATE conviction, given high valuations and moderate expected returns (~8% pretax over 12–18 months). ARKG's top holdings—10x Genomics, Twist Bioscience, and Tempus AI—drive performance but trade at expensive revenue multiples, requiring strong execution to justify current prices. While ARKG offers exposure to transformative genomics and AI-enabled drug discovery, much of the optimism is already priced in, leaving little margin for error or disappointment.

ARKG: Revolutionary Science, Unremarkable Returns

Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You

President Donald Trump has disclosed over 20,000 stock trades made over the past 12 months. The trades, which the White House says Trump has no knowledge of, span a wide range of sectors and dollar amounts.

Donald Trump, Cathie Wood Bet on the Same 32 Stocks – Some Might Surprise You

Beyond Cellular Models: Longevica Capitalizes on World's Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline

SAN FRANCISCO & NEW YORK--(BUSINESS WIRE)---- $ARKG #AI--Longevica forms a star SAB to turn its $13M, 16k-subject mammalian study into AI-driven drug discovery, pet health, and novel human therapies.

Beyond Cellular Models: Longevica Capitalizes on World's Largest In Vivo Longevity Study to Form Star-Studded Advisory Board and Unlock Human Health-and-Lifespan Pipeline

3 Analysts, 3 Trades to Make Today

Louis says buy the AI dip

3 Analysts, 3 Trades to Make Today

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

The biotech sector has a new catalyst beyond GLP-1 drugs. Moderna Inc (NASDAQ:MRNA) and Merck & Co Inc's (NYSE:MRK) positive Phase 3 results for a personalized mRNA cancer vaccine could revive investor interest in genomics, immunotherapy and precision medicine ETFs.

Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs

Zacks Investment Research

Best-Performing ETF Areas of August

August delivered strong gains across shipping, crypto, precious metals, biotech, copper, uranium and cloud software ETFs.

Best-Performing ETF Areas of August

ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable

ARK Genomic Revolution ETF remains a buy as its valuation improves and technical support emerges after a 15% correction from July highs. ARKG's portfolio is concentrated in small- and mid-cap biotech, with top 10 holdings comprising 59% and a long-term EPS growth rate now at 10.7%. Despite weak seasonality and high volatility, ARKG's rising 200-day moving average and strong support at $34–$35 provide a favorable risk-reward setup.

ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable

24/7 Wall Street

ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?

The ARK Genomic Revolution ETF (CBOE:ARKG) and the Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) look like siblings on any screener.

ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins?

Zacks Investment Research

Best ETF Areas of June

Biotech, China, insurance and healthcare ETFs led June gains as strong earnings, AI optimism and easing geopolitical fears lifted markets.

Best ETF Areas of June

June's Top ETFs: Biotech & China Semiconductors Surge

June has been a month full of excitement in the ETF market. While commercial space and AI infrastructure attracted a significant amount of investor attention, biotechnology exposure comprises four out of the five top-performing equity ETFs as of June 29.

June's Top ETFs: Biotech & China Semiconductors Surge

See News Rankings

Price charts implemented using Lightweight Charts™